TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07877038: A Study to Evaluate the Pharmacokinetic Characteristics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Hepatic Impairment and in Those With Normal Hepatic Function

Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07877038 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07877038 Rescue Dossier →